ACRS vs. STOK, SANA, MRVI, URGN, AUTL, CDXC, CDTX, ABUS, EOLS, and UPB
Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), Cidara Therapeutics (CDTX), Arbutus Biopharma (ABUS), Evolus (EOLS), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.
Aclaris Therapeutics vs. Its Competitors
Stoke Therapeutics (NASDAQ:STOK) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
Stoke Therapeutics currently has a consensus price target of $23.20, indicating a potential upside of 98.46%. Aclaris Therapeutics has a consensus price target of $9.71, indicating a potential upside of 565.36%. Given Aclaris Therapeutics' higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Stoke Therapeutics.
In the previous week, Stoke Therapeutics had 11 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 14 mentions for Stoke Therapeutics and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.70 beat Stoke Therapeutics' score of 0.18 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.
Stoke Therapeutics has a net margin of 26.33% compared to Aclaris Therapeutics' net margin of -732.42%. Stoke Therapeutics' return on equity of 19.08% beat Aclaris Therapeutics' return on equity.
98.3% of Aclaris Therapeutics shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by company insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Stoke Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
Stoke Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
Summary
Stoke Therapeutics beats Aclaris Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Aclaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclaris Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ACRS) was last updated on 7/8/2025 by MarketBeat.com Staff
